Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway
Journal
Cancer Research
Journal Volume
65
Journal Issue
21
Pages
9807-9816
Date Issued
2005
Author(s)
Ni J.
Wen X.
Yao J.
Yin Y.
Zhang M.
Xie S.
Chen M.
Simons B.
Chang P.
Di Sant'Agnese A.
Messing E.M.
Yeh S.
Abstract
Epidemiologic studies suggested that vitamin E has a protective effect against prostate cancer. We showed here that tocopherol-associated protein (TAP), a vitamin E-binding protein, promoted vitamin E uptake and facilitated vitamin E antiproliferation effect in prostate cancer cells. Interestingly, without vitamin E treatment, overexpression of TAP in prostate cancer cells significantly suppressed cell growth; knockdown of endogenous TAP by TAP small interfering RNA (siRNA) in nonmalignant prostate HPr-1 cells increased cell growth. Further mechanism dissection studies suggested that the tumor suppressor function of TAP was via down-regulation of phosphoinositide 3-kinase (PI3K)/Akt signaling, but not by modulating cell cycle arrest or androgen receptor signaling. Immunoprecipitation results indicated that TAP inhibited the interaction of PI3K subunits, p110 with p85, and subsequently reduced Akt activity. Constitutively active Akt could negate the TAP-suppressive activity on prostate cancer cell growth. Moreover, stable transfection of TAP in LNCaP cells suppressed LNCaP tumor incidence and growth rate in nude mice. Furthermore, TAP mRNA and protein expression levels were significantly down-regulated in human prostate cancer tissue samples compared with benign prostate tissues as measured by reverse transcription-PCR, in situ hybridization, and immunohistochemistry. Together, our data suggest that TAP not only mediates vitamin E absorption to facilitate vitamin E antiproliferation effect in prostate cancer cells, but also functions like a tumor suppressor gene to control cancer cell viability through a non-vitamin E manner. Therefore, TAP may represent a new prognostic marker for prostate cancer progression. ?2005 American Association for Cancer Research.
SDGs
Other Subjects
alpha tocopherol; androgen receptor; ascorbic acid; binding protein; delta tocopherol; gamma tocopherol; messenger RNA; phosphatidylinositol 3 kinase; protein kinase B; protein p110; protein p85; small interfering RNA; tocopherol associated protein; tumor suppressor protein; unclassified drug; animal experiment; animal model; animal tissue; apoptosis; article; cancer cell culture; cancer growth; cancer inhibition; cell assay; cell cycle; cell survival; cell viability; controlled study; down regulation; drug effect; drug uptake; enzyme activity; enzyme inhibition; enzyme regulation; enzyme subunit; gene expression; genetic transfection; human; human cell; human tissue; immunohistochemistry; immunoprecipitation; in situ hybridization; knockout gene; male; mitosis inhibition; mouse; nonhuman; nude mouse; priority journal; prognosis; prostate cancer; protection; protein expression; protein function; protein protein interaction; regulatory mechanism; reverse transcription polymerase chain reaction; signal transduction; tissue microarray; tumor suppressor gene; 1-Phosphatidylinositol 3-Kinase; Animals; Carrier Proteins; Cell Growth Processes; Cell Line, Tumor; Gene Expression; Humans; Lipoproteins; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Transplantation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Trans-Activators; Transplantation, Heterologous; Vitamin E
Type
journal article